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AbstraCf
THE EFFECTS OF LEVAMISOLE, CORYNEBACTERIUM PARVUM,
AND UNBLOCKED LYMPHOCYTES ON MICE INJECTED WITH
HERPES VIRUS TYPE 2-TRANSFORMED CELLS
by Linda Martin Kelln
The association between herpes simplex virus type-2 and carcinoma
of the cervix is becoming increasingly strong (Rawls, et�-, 197 6 ;
Rapp and Duff, 1974; Hollingshead, et

tl-,

1973). This study demon

strates the ability of certain known immunostimulators to beneficially·
alter the immune status of mice injected with HSV-2 transformed cells.
Balb/c mice were randomly divided into 6 groups.

Group 1 mice

were used as negative controls and received no tumor cell injection.

All other groups received subcutaneous injections of 1 x 10 6 cells/
mouse.

Tumor therapy by means of irrmunostimulation was started for

each group of mice 1 day after the initial tumor cell injection and
proceeded on a weekly basis for a total of 7 weeks before sacrifice.
Group 1 non-injected mice received no tumor therapy.

Group 2

mice were used as positive controls and also received no immuno�
stimulatory therapy.

Mice in group 3 received 200 µgm of levamisole,

a non-specific immune stimulator.

Group 4 mice were given 300 µgm

of heat and formalin killed Corynebacterium parvum which is known to
non�specifically stimulate macrophage populations.

Mice in group 5

received unblocked lymphocytes at a concentration of 4 x 106 cells/
mouse.

Group 6 mice received a combination therapy of levamisole,

C. parvum and unblocked lymphocytes.
Weekly measurements of tumor volume were made using vernier
calipers. At the time of sacrifice specific cytotoxicity tests
were performed. These included the antibody-dependent cell-mediated
cytotoxicity (ADCC) test, the blocking factor (BF) assay and the
cytolytic T-lymphocyte (CTL) test. The lymphocyte transformation test
using phytohemagglutinin, a T-cell mitogen, was also performed at
the time of sacrifice, using mouse spleen cells.
Levamisole was unable to significantly stimulate the immune
status of group 3 animals and showed no apparent benefit in reducing
tumor volume. Unblocked lymphocytes administered to group 5 mice
may have had some stimulatory effect upon the immune status of the
tumor mice, but it was not significant. Tumor volume was the greatest
for group 5 mice and significantly higher than for those mice treated
only with C. parvum (group 4) or the combination therapy (group 6).
ADCC and BF cytotoxicity results did tend to indicate that C.
parvum alone and in combination with levamisole and unblocked lymphoctyes was able to stimulate the immune responses, of group 4 and 6
animals. Tumor volumes were the lowest for these 2 groups. Combination group 6 mice had the lowest tumor incidence also.
It was concluded from this study that the combination of levamisole, C. parvum and unblocked lymphocytes did have an enhancing
effect upon the immune status of tumor hosts, which may actually aid
in lowering tumor incidence and progression.
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Introduction
It has long been established that viruses play a major role in
the development of certain animal tumors (Jawetz, et al., 1980;
Friend, 1965, 1959; Gross, 1951). However, evidence as to the function
of viruses in human neoplasia has been much slower in evolving
(Hellstrom and Hellstrom, 1969).
Major associations have been suggested between carcinoma of the
cervix and herpes simplex virus (HSV) (Rawls, et al., 1976; Nahmias,
et al., 1976; Hollinshead, et al., 1973, 1976; Aurelian, 1973;
Aurelian, et al., 1973; Frenkel, et al., 1972). Serological evidence
is strong in supporting such a relationship. However, this is not
absolute proof that HSV is the major cause of cervical cancer.
As early as 1970, Tarro and Sabin isolated nonvirion antigens
specific for HSV 1 and HSV 2. Using this information, specific antibodies for HSV 2 were found in association with cervical carcinoma
patients (Rawls, et al., 1976; Hollinshead, et al., 1973; Aurelian,
1973; Aurelian, et al., 1973). These antibodies are type specific,
unlike the common herpes neutralizing antibodies. Specific tumorassociated antigens are responsible for type specific antibodies
and have been clearly associated with exfoliating cervical carcinoma
cells (Rapp and Duff, 1974).
Human cervical tumor cells have been found to contain certain
DNA sequences corresponding to portions of the HSV 2 genome (Frenkel,
et al., 1972; Roizman and Frenkel, 1973). Viral herpes DNA, though

in fragments or inactivated, may be potentially carcinogenic (Wise,
et al., 1977; Hilleman, 1976; Graham, et al., 1973). This is one
reason the work towards an effective herpes vaccine has been difficult.
Transforming Potential of Herpes Simplex Virus
Many investigators have shown that inactivated herpes simplex
viruses are capable of transforming hamster, mouse and human embryonic
fibroblasts into potentially malignant cell lines (Duff and Rapp, 1971,
1973; Rapp and Duff, 1974; Munyon, et al., 1972; Boyd and Orme, 1975;
Boyd, 1976; Kucera and Gusdon, 1976). Evidence for the HSV transforming
potential has been collected. No actual virus particles have been
recovered from the transformed cells, but virus-like particles have
been found in the nuclei of some of them (Duff and Rapp, 1971). Boyd,
et al., (1975), discovered specific HSV 2 antigens in transformed 238
mouse fibroblast cells as well as specific antibodies to these antigens
using the indirect immunofluorescence technique.
Tumorgenicity of such transformed cell lines is well documented.
Duff and Rapp (1971, 1973) were able to transform hamster fibroblasts
using either HSV 1 or HSV 2. All of these cell lines, however, did
not produce tumors when injected into syngeneic animals. Boyd and
Orme (1975) used HSV 2 (Savage strain) to transform 238 mouse fibroblasts (Balb/C mice) into a malignant cell line (H238 cells). The
transformed H238 cells produced tumors with 100% incidence when injected
6
at 1 x 10 cells/mouse (Boyd and Orme, 1975).

Immune Responses to Tumor Challenge .
Through the years the theory of immune surveillance, associated
primarily with infections, has been widely accepted (Burnet, 1959,
1961). More recently it has been found that primary and secondary
immunodeficiencies can also lead to higher incidence of malignancy
(Good, 1972). Some investigators, however, have challenged this
concept and put forth other potential explanations for the immune
system's relationship to tumor development (Prehn and Main, 1957;
Schwartz, 1972, 1975). Surveillance mechanisms would eliminate tumor
cells as they arose. Much evidence instead supports the idea of
immunostimulation or immunoregulation induced by the presence of
tumor-associated antigens (Schwartz, 1972, 1975; Kirchner, et al, 1974).
There is, however, a well established relationship between immunocompetence and prognosis in progressive human cancer (Hersh, et al.,
1976; Miller, 1968). Some patients with cancer have been shown to
have deficiencies in their immune system. These deficiencies may
make it very hard for the immune system to effectively destroy tumor
cells (Hersh, et al., 1970).
There is much evidence that T-lymphocytes and their by-products
play a major role in tumor immunology (Bansal, 1978; Tursi, et al.,
1968). Lymphocytes directly cytolytic for target tumor cells have been
found to be of thymic origin (Plata, et al., 1976). Tumor antigens are
apparently able to activate anti-tumor responses in T-cells (Hellstrom
and Hellstrom, 1969). HSV tumor-associated antigens are often found

as antecedents in patients with squamous carcinoma who have suppressed
cell mediated immune (CMI) responses (Hollinshead, et al., 1976).
B-cells, the antibody-producing lymphocytes, have not been found
to play as obvious a role in tumor immunology as T-cells. Mechanisms
have been found however, which indicate that they appear to be an
integral part of the defense against tumors (Nahmias, et al., 1976;
Germain, 1979). Serum globulins (antibodies) with the aid of null (K)
cells are able to lyse HSV infected cells as well as tumor target
cells (Pfizenmaier, et al., 1977; Nahmias, et al., 1976; Ragen-Zisman
and Bloom, 1974; Germain, 1979). Serum blocking factors, which are•
thought to be antibodies and/or antibody-antigen complexes, have been
shown to decrease the ability of effector T-cells to destroy target
tumor cells (Nowotny, et al., 1976; Ran, et al., 1976; Baldwin, et al.,
1972; Hellstr6m, et al., 1971; Hellstr6m, et al, 1970).
Macrophages have the ability to phagocytize and degrade tumor
cells. It is thought that the presence of a large number of macrophages at the tumor site may play a major role in preventing or slowing
metastatic spread (Alexander, 1976; Eccles and Alexander, 1974; Evans,
1972). T-lymphocytes and their products may 'arm' otherwise normal
macrophages, and thus activate them for attack against specific tumor
cells (Evans and Alexander, 1972a, 1972b; Evans, et al., 1972). It
has also been suggested that cancer patients having good monocyte
(macrophage) chemotactic responses (MCR) possess more effective cytolytic T-cells. In fact, a high MCR may be an indicator of effective

host response to disease in general (Boetcher and Leonard, 1974). If
tumor cells, or effector cells responding to tumors, are able to attract
macrophages to the tumor site, other factors must be considered.
Evidence shows that tumors somehow interfere with peripheral blood
monocytes migrating to locations of inflammation. Therefore, certain
states of anergy in cancer patients may be partially due to macrophage
cells which are unable to fulfill their role in immune recognition
(Eccles and Alexander, 1974b).
Certain lymphocyte-like cells of unknown lineage have been
designated natural killer (NK) cells. These cells are present in the
normal individual and are able to lyse tumor cells by direct contact,
although the mechanism by which this takes place is not known (Germain,
1979).
Methods for Measuring Cell-Mediated Immunity
The spleen houses the largest collection of reticuloendothelial
cells in the body which function in removing foreign material. During
the growth of a tumor, the spleen is often found to enlarge (Nutter,
et al., 1980; Rowland, et al., 1973). The proportions of T- and 6lymphocytes as well as phagocytic macrophages becomes markedly altered
with respect to those found in normal spleens. The T-cell population
is usually between 5 and 10 percent lower than in control groups, and
the proportions of macrophages drestically increases (Kirchner, et al.,
1974; Visakorphi, 1973).
A commonly used method of measuring lymphocyte response in vitro
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is the lymphocyte transformation test (LTT). Phytohemagglutinin (PHA),
is T-cell mitogen, is a glycoprotein extracted from the kidney bean
(Fisher and Mueller, 1968; Nowell, 1960). Unimpaired T-cells are
stimulated by PHA to become metabolically more active and form large
blast-like cells with high mitotic indices (Greaves, et al., 1974;
Oppenheim and Perry, 1965). It is known, however, that lymphocytes
collected from tumor-bearing hosts are generally less stimulated by
PHA than are normal cells. The reactivity of such cells is therefore
an important measurement of the tumor hosts' immune status (Gillette
and Boone, 1975; Sample, et al., 1971; Hersh and Oppenheim, 1968;
Tursi, et al., 1968).
In vitro cytotoxicity tests (CTT) are more specific measures of
anti-tumor activity and, therefore, provide more information with
respect to the ability of the host to combat the tumor (Trejosiewicz,
et al., 1978). Serum blocking factors as well as antibody dependent
and direct T-cell cytotoxicity can be measured (Germain, 1979;
Trejdosiewicz, et al., 1978). The ability of effector spleen cells
to destroy target tumor cells provides valuable information regarding
the immune status of the tumor host (Lausch, et al., 1975; Hellstrom
and Hellstrom, 1974; Baldwin, et al., 1972; Ran, et al., 1976).
Immunotherapy in Tumor Hosts
That status of the immune system of a tumor host plays a role in
determining whether regression or progression of the neoplastic state
will occur. It is thought that certain types of treatment using

immunopotentiators are of benefit to some cancer patients (Morton,
1978; Sjorgren, 1977). The combination of chemotherapy and immunostimulation has been shown to be very effective in treating certain
malignancies in animal models (Bansal and Bansal, 1978; Bansal, et al.,
1978; Fisher, et al., 1975; Pearson, 1972; Currie and Bagshawe, 1970).
Levami sole
At one time levamisole was used only as an antihelminthic drug
(Goldstein, 1978; Lancet, 1975). It has been reported that
chemoimmunostimulation using levamisole has restored CMI responses to
normal levels in patients having rheumatoid arthritis, bronchoaenic
carcinoma, and Hodgkins disease (Huskisson, et al., 1976; Study Group
for Bronchogenic Carcinoma, 1975; Levo, et al., 1975). Delayed skin
hypersensitivity reactions have been shown to convert from negative
to positive after treatment with levamisole (Verhaegen, 1973). Experimentation has shown that levamisole restores host defenses only in
immunodeficient subjects. Little evidence suggests that this chemical
is able to stimulate a normally functioning immune system (BruletRosset, et al., 1978; Goldstein, 1978; Amery, 1976). The mode of
action of levamisole on the immune system is not fully understood. It
is known that its chemical structure is similar to that of a polypeptide
hormone secreted by the thymus which aids the differentiation of
precursor cells into T-lymphocytes (Basch, et al., 1974; Goldstein, 1974;
Twomey, 1974; Komuro, 1973; Goldstein, 1970). A diagram of levamisole's
structure is shown in Figure 1.

CL

FIGURE 1!

LEVAM I SOLE

- 2, 3, 5, 6 - tetrahydro b thiazole hydrochloride

- phenyl-imidazo
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Sadowski (1975), showed that levamisole was effective in limiting
metastasis due to HSV 1-transformed cells in hamster models. The development of tumors induced by 1,2-dimethylhydrazine were also inhibited
in rats by the injection of levamisole in combination with unblocked
lymphocytes (Bansal and Bansal, 1978).
While the potential benefit of levamisole as an immunostimulator
appears great, it seems that these benefits are does related. Excessive amounts of the drug can be immunosuppressive rather than immunostimulatory. Tumor enhancement has been noted in a number of experiments (Focan, 1979; Sampson, 1978; Sampson, et al., 1977).
Granulocytosis, skin rash, and febrile illness due to excessive
levamisole therapy have also been reported (Focan, 1979; Symoens,
et al., 1978).
Corynebacterium parvum
The bacillus Calmette-Guerin (BCG) has been shown to be effective
in providing some protection to experimental animals inoculated with
syngeneic tumor cells (Weiss, et al., 1961; Old, et al., 1960).
However, this organism does have to be administered as a live preparation which has led to certain adverse side effects. It also
must be administered directly into the tumor site and preferably at
the time of tumor cell inoculation (Zbar, et al., 1974; Zbar, et al.,
1970). Although the practicality of this organism in treating human
cancer is questionable, it has led to studies involving the bacterium
Corynebacterium parvum.
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C. Parvum is effective in protecting against certain common
becterial infections, such as infection due to S. aureus (Adlam, et al.,
1972). Administered in a heat and formalin killed suspension, it has
been shown to non-specifically enhance the immune system of tumorbearing hosts. Activation of phagocytic macrophages seems to be the
primary immunostimulatory response to this bacterium (Ghaffer, et
al., 1975; Ghaffer, et al., 1974; Wolmack, 1974; Keller, 1973).
In animal models C. parvum alone has successfully reduced death
rates due to tumor and/or increased longevity (Fisher, et al., 1975;
Halpren, et al., 1966; Woodruff, 1966). Israeli (1975, 1976) has
shown that in cancer patients, either regression or slowing of tumor
growth can be accomplished using C. parvum treatments. Others report
that the responses to C. parvum treatments may be varied. In 1966,
Woodruff reported that tumor development was delayed by administration
of C. parvum, but growth progressed as quickly as in those without
treatment once the tumors did develop. Fisher, et al., (1970) reported
on the other hand that there was a reduction in tumor growth rate
rather than a delay in tumor appearance. In vitro, the cytotoxicity
of lymph node cells from tumor-bearing hosts increased with the use
of C. parvum (Fisher, et al., 1974). Because of these and other
experiments, specific tumor vaccines using killed tumor cells and
C. parvum have been employed in reducing tumor progression in mice.
The results showed that the tumor size decreased and life expectancy
increased overall (Scott, 1975). In these experiments, however, C.
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parvum without the killed tumor cells provided no positive results.
C. parvum, unlike some immunostimulators, rarely produces any
observable side effects tn humans (Likhite, et al., 1974). Because of
this it may prove to be a valuable tool in the treatment of cancer
patients. Although it is unlikely that C. parvum would significantly
influence advanced malignancies, if used at the onset of disease or
at the time of excisional surgery it is possible that the host's
immune system would be enhanced to such an extent as to successfully
combat the tumor cells (Fisher, et al., 1970).
Unblocked T-Lymphodytes
Certain blocking factors may limit the cytotoxic effect of Tlymphocytes upon tumor cells both in vivo and in vitro. It has been
shown that thoracic duct lymphocytes transferred between HL-A compatible
siblings increase the immune response of the recipient against tumor
progression (Yonemoto, 1976). Other experiments use the lymphocytes
from the tumor-bearing animal (Doyle, 1974). These lymphocytes are
washed and returned to the same host animal. It has been suggested
that such a washing may activate or unblock the T-cells, thereby
increasing their effectiveness against tumor cells once injected
back into the host. Such an increase in cytotoxicity has been shown
in vitro (Doyle, 1974). Unblocking lymphocytes with the use of proteo1y-tic enzymes has also been successful, thereby degrading the blocking
factor inside the host. Patients in an anergic state have developed
increased delayed skin hypersensitivity reactions after the unblocking

12

of their T-cells (Thornes, 1974).
Combination therapy
Combination therapy studies have been performed in the past using
C. parvum and chemotherapy (Israeli, 1976; Pearson, 1972; Currie and
Bagshawe, 1970), levamisole and BCG (Bruley-Rasset, et

tl·,

1978), and

levamisole in c'ombination with unblocked lymphocytes (Bansal and
Bansal, 1978).

However, it has been demonstrated by Bansal, et

(1978) that the combination of levamisole,

tl·,

-f. parvum, and unblocked

lymphocytes given in several successive doses effectively inhibits
progressive tumor growth in rats with 1,2-dimethylhydrazine induced
tumors.

MATERIALS AND METHODS
Mice
Five week old female Balb/c mice were obtained from the Jackson
Laboratory (Bar Harbor, Maine). They were separated into groups,
marked and housed eight to a cage for seven weeks before the project
began. The.mice were fed Purina Lab Chow ad libitum and given tap
water through the experiment.
H238 Tumor Cells
Originally a Balb/c embryonic fibroblast cell line (238) was
transformed by UV - inactivated herpes simplex virus type 2 (Savage
strain) into a malignant tumor cell line (H238). Our lab obtained
the H238 cell line from Dr. Ann Boyd, National Cancer Institute,
Frederick, Maryland.
Media
H238 cells were grown in Dulbecco's Modified Eagle Medium (Grand
Island Biological Company, Grand Island, New York). Roswell Park
Memorial Institute (RPMI) - 1640 medium (Grand Island Biological
Company, Grand Island, New York) was used in any procedure involving
lymphocytes. Both were supplemented with 10% fetal calf serum (Reheis
Chemical Company, Phoenix, Arizona), 100 units penicillin (Pfizer, Inc.,
New York, New York), 100 pg/mt streptomycin (Eli Lilly and Company,
Indianapolis, Indiana), 50 pg/mt tetracyline (Lederle Laboratories,
Pearl River, New York), 100 pg/mt fungizone (E.R. Squibb and Sons,
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Inc., Princeton, New Jersey).
All media were prepared in double distilled water.
Buffers
Tris buffered saline (TBS) was used in all washing procedures
throughout the experiment. The formula for TBS is as follows: 0.14 M
NaCl, 5.1 mM KC1, 0.38 mM Na 2HPO4 • 7H20, 0.56 mM Dextrose (anhydrous),
0.025 M Tris-(hydroxymethyl) aminomethane (Schwartz/Mann), 0.018 M
conc. HC1, 0.49 mM MgC1 2 • 6H20 and 0.9 mM CaC1 2.
ACK (ammonium chloride potassium) lysing buffer was used to lyse
unwanted red blood cells. The formula for ACK lysing buffer is as
follows: 0.01 M KHCO3, 0.16 M NH4C1 and 0.1 mM Na2EDTA.
Double distilled water waS used to prepare all buffers.
Radioactive Compounds
125 I-iododeoxyuridine ( 125IUdR

Amersham, England) was used as

the radioisotope to label the DNA in the cytotoxic assay procedures.
Tritiated thymidine ( 3H-Thymidine, New England Nuclear, Boston,
Mass.) was used as the radioisotope to label the DNA in the lymphocyte
transformation tests.
Tumor Cell Injection
H238 cells were harvested by trypsinization, suspended and
washed three times in TBS to remove any complete Dulbecco's medium.
The cells were counted in a hemacytometer. The cell suspension was
adjusted to a concentration of 3.3 x 106 cells/m5. A tuberculin
syringe (Sherwood Medical Industries Inc., Deland, Florida) was used
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to make a 0.3 mk subcutaneous (s.c.) injection of the cell suspension
into the lateral portion of the right hind leg, delivering 1 x 106
cells/mouse.
Treatment of Control and Therapy Mice
Twenty-four mice were originally used for each of the six experiimental groups presented in Table I.
Negative controls (group I) were not injected with H238 tumor
cells and received no anti-tumor therapy. Positive controls (group 2)
were injected s.c. with H238 tumor cells but received only saline in
lieu of anti-tumor therapy. Mice in groups 3, 4, 5 and 6 were all
6
injected s.c. with H238 tumor cells at a concentration of 1 x 10
cells/mouse with immunostimulatory therapy beginning the following
day and at weekly intervals thereafter.
Two hundred micrograms (pg) of levamisole (Janssen Pharmaceutical,
New Brunswick, New Jersey) was administered intraperitoneally (i.p.)
to all group 3 mice. Three hundred pg of inactivated Corynebacterium
parvum (Burroughs Wellcome, North Carolina) was administered i.p.
6
into group 5 mice at a concentration of 4 x 10 cells/mouse.
These cells were obtained from a female •Balb/c mouse with a progressive
H238 tumor twenty-four hours prior to the scheduled therapy. The
mouse was euthanized by CO2 and the spleen was removed. A single-cell
suspension was obtained by teasing the spleen with 2 wooden applicator
o
sticks. ACK lysing buffer was added for 4 minutes at 4 C to remove
red blood cells from the spleen cell suspension. The remaining cells

TABLE I,

TREATMENT SCHEDULE AND TEST SYSTEMS
INITIAL
INJECTION TRT. #1

TRT. #2

TRT. #3

TRT. #4

TRT. #5

TRT. #6

TRT. #7

SACRIFICE

PANEL #1

DEC. 15

DEC. 16

DEC. 23

DEC. 30

JAN. 6

JAN. 13

JAN. 20

JAN. 27

FEB. 3

PANEL #2

DEC. 22

DEC. 23

DEC. 30

JAN. 6

JAN. 13

JAN. 20

JAN. 27

FEB. 3

FEB. 10

PANEL #3

DEC. 29

DEC. 30

JAN. 6

JAN. 13

JAN. 20

JAN. 27

FEB. 3

FEB. 10

FEB. 17

PANEL #4

JAN. 5

JAN. 6.

JAN. 13

JAN, 20

JAN. 27

FEB. 3

FEB. 10

FEB. 17

FEB, 24

PANEL #5

JAN. 12

JAN. 13

JAN. 20

JAN. 27

FEB. 3

FEB. 10

FEB. 17

FEB.24

MAR, 3

PANEL #6

JAN. 19

JAN. 20

JAN. 27

FEB. 3

FEB. 10

FEB. 17

FEB. 24

MAR. 3

MAR. 10

TEST SYSTEMS
GROUP 1 - NON-INJECTED MICE ( NEGATIVE CONTROLS )
GROUP 2 - INJECTED MICE ( 1-1238 CELLS - 1)(106 CELLS/MOUSE ), NO TREATMENT ( POSITIVE CONTROLS )
GROUP 3 - INJECTED MICE TREATED WITH LEVAMISOLE - 200 11G/mousE
GROUP 4 - INJECTED MICE TREATED WITH CORYNEBACTERIUM PARVUM - 300 PG/MOUSE
GROUP 5

INJECTED MICE TREATED WITH UNBLOCKED LYMPHOCYTES - 4)(106 CELLS/MOUSE

GROUP 6 - INJECTED MICE TREATED WITH COMBINATION OF TREATMENTS 3,4 & 5
MICE RECEIVED AT 5 WEEKS OF AGE - INJECTION OF H238 CELLS AT 12 WEEKS OF AGE
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were washed hourly for 4 hours using RPM-1640 medium. After the
fourth washing the cells were resuspended and refrigerated overnight
in RPMI-1640 medium supplemented with 0.2% normal mouse serum. Before
use the cells were washed 3 times and resuspended in TBS at a concentration of 20 x 10

6

cells/m9.. A combination of treatments applied

to groups 3, 4, and 5 was administered i.p. to all group 6 mice.
Four mice from each group (24 total mice) were injected with
tumor cells or saline (negative controls) and started on a specific
therapy once a week which continued for seven weeks. All groups
injected with tumor cells in any one week were considered a panel.
Treatment for each group within a given panel proceeded on a weekly
basis for a total of seven consecutive weeks before sacrifice as
indicated by Table 1.
Labeling H238 Target Cells
Cells were split 24 hours prior to labeling and cultured in
50% Dulbecco's complete medium and 50% RPMI - 1640 complete medium
(1/2-1/2 medium). The morning the cells were to be labeled they were
trypsinized from the flasks and taken up in fresh 1/2-1/2 medium. The
cells were then counted in a hemacytometer and adjusted to a final
concentration of 1.6 x 106 cells/m2 in 'conditioned' medium, the
actual growth medium used to culture the target cells 24 hours
prior to trypsinization.
Four mks of this cell suspension was added to 4 mk of labeled
medium. The latter was preapred by combining 0.42mk of 10-4
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fluorodeoxyuridine (FUdR) in RPMI -1640 medium, 3.36 mk conditioned
medium and 0.48 m2. of

125
IUdR (final concentration 3 pCi per mk).

Two mk, of the combined cell suspension and labeled medium was
pipetted into each of 4 small tissue culture flasks and incubated
in a 5% CO„ incubator at 37

0

C for 4 hours. After this period the

labeled medium was removed and the cells were gently washed 3 times
in the flasks with conditioned medium. Cells were then trypsinized,
resuspended in 2 mk conditioned medium, counted in a hemacytometer •and
5
adjusted to a concentration of 6.5 x 10 cells/m2 using 1/2-1/2 medium.
Effector Cells
Spleens were removed from all test and control animals, weighed,
and then placed in 3 m9 RPMI - 1640 medium. The spleens were then
teased with wooden applicator sticks until all cells were released.
The suspensions were centrifuged and the supernate discarded.
ACK lysing buffer was added to remove red blood cells. The tubes
were centrifuged again and the supernate discarded. The remaining
cells were resuspended in RPMI - 1640 medium, counted in a hemacytometer and adjusted to a final concentration of 2.5 x •10

7

cell/mk,

using 0.2% trypan blue as an indicator of cell viability.

Target Cell Incubation - CTT
1. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
Labeled H238 target cells adjusted to a concentration of 6.5 x
cells/m2, were added in 0.1 mk aliquots to 1.2 mk of each test

05
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mouse serum sample (groups 2 - 6 mice) obtained that day via cardiac
puncture (sera were all diluted 1:4 before cells were added to provide
sufficient volume for test procedures). Target cells were also added
in the same manner to a 1.2 mk sample of negative control mouse
serum (group 1 mice) harvested that day. These cell suspensions
were then mixed and dispensed in 0.1 mk aliquots (5 x 103 cells/
well) to each of three microculture plate (Costar, Cambridge, Mass.)
wells for every test and control animal being assayed for ADCC that
day. Cells were incubated for 11/2 hours in an atmosphere of 5% CO2
in air at 37°C.
2. Blocking Factor (BF)
Labeled target cells adjusted to a final concentration of
5
6.5 x10 cells/mk Wereadded in 0.1 mk aliquote to 1.2 mk of each
test mouse serum sample harvested that day. Target cells were also
dispensed into 1.2 mk samples of negative control sera. Target cells
suspended in test sera were dispensed in 0.1 mk aliquote (5 x 103
cells/well) to each of three wells for every test animal. Target
cells suspended in the negative control sera iwere also dispensed
into three wells for every test animal assayed that day. The cells
were incubated for 11/2 hours in a 5% CO2 environment at 37 C.
3. Cytolytic T-Lymphocytes (CTL)
Labeled target cells adjusted to a concentration of 6.5 x 105
cells/m9 were added in 0.1 mk aliquots for every 1.2 mk RPMI - 1640
medium. One-tenth mk aliquots of this cell suspension were dispensed
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into each of three wells (5 x 10 3 cells/well) for every test and
negative control animal and incubated for 1\ hours in a 5%
environment at 3 7° C.

co 2

4. Non-Specific Lysis (NSL)
Labeled target cells were added in 0.1 mi aliquots into 1.2 mi
RPMI - 1640 medium. One-tenth mi aliquots of this suspension were
incubated for 1\ hours in a 5% CO 2 environment at

37

°

C.

Cytotoxicity Assays
All plates wer·e turned upside down and drained to remove any
unattached target cells 1\ hours after the labeled cells were
originally added. Effector spleen cells (test or negative control)
adjusted to a conc�ntration of 2.5 x 107 cells/mi were then added

to each well in 0.1 mi aliquots, to produce an effector to target
ratio of 500: 1.
Test animal spleen cells were added to wells involved in the
blocking factor, blocking factor control and cytolytic T-lymphocyte
assays. Negative control spleen cells were added to wells set-up
for the antibody-dependent cell-mediated cytotoxidty and ADCC
control assays along with the CTL (Natural Killer - NK) control
wells. One-tenth mi RPMI - 1640 medium was added to each of the
twelve NSL wells. The plates were incubated for a total of 2 0 hours
in a 5% CO 2 incubator at

°
37

C.
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At the end of this 20 hour period the plates were harvested with
a Multiple Automatic Sample Harvester (Mash II, Microbiological
Associated, Inc., Bethesda, Maryland). The fluid contained in the
plate wells was collected into one set of tubes (supernate tubes)
and the 1251 released during the incubation period was counted in
a gamma counter. Unattached who1 e ce11 s were collected on fi1 ter
.paper discs and added to the second set of tubes. The cells con
taining unreleased isotope were collected into a second set of tubes
after washing with sodium dodecyl sulfate (Sigma Chemical Co., St.
Louis, Mo.) the filter paper discs were added and the tubes were
counted in a gamma counter. These results plus the supernate tube
results provided total counts per minute (cpm). The results of the
release were expressed using an average of the three wells set-up
for each test and negative control animal for the three cytotoxicity assays.
NSL Results Total % NSL

=

NSL cpm supernate
NSL tota1 cpm

x

lOO%

ADCC Results ADCC
ADCC
ADCC
ADCC
Total % ADCC

=

control cpm supernate x lOO% =
control total CPM
test cpm supernate x lOO%; y
test tota1 cpm

(Y-X - (X - NSL)
X - NSL

0

X

1QQ%

x
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BF Results BF control cpm supernate
BF control total cpm

)‹ 100% = X

BF test cpm supernate
x 100% _
- Y
BF test total cpm
Total % BF = (X - NSL)

(Y - NSL)

(X - NSL)
CTL Results CTL control (NK) cpm supernate x 100% = V
CTL control (NK) total cpm
(V - NSL)
(100 - NSL) x 100% = W
CTL test cpm supernate x 100% = X
CTL test total cpm
Total % CTLL= (X - NSL)
(100 - NSL)

100% = Y

Net % CTL = (Y - W) = net % lysis
Lymphocyte Transformation Test- LTT
The same spleen cells- (effector cells) obtained and prepared for
the cytotoxicity tests were used in the LTT assay.- The cells were
tested for viability by trypan blue exclusion. The cells were then
counted in a hemacytameter and the concentration adjusted to 1 x 106
cells/mi. From these spleen cell suspensions, 0.1 mk aliquots were
dispensed into microculture plate wells. Six wells were set-up for
every test animal and control animal. Phytohemagglutinin (PHA-P
Wellcome Research Laboratories, Beckenham, England) adjusted to a
dillution of 1:60 (determined by prior assay) was dispensed into three
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of six wells set up for every :
animal. Complete RPMI - 1640 medium
was dispensed into the remaining three wells set-up for each animal.
The plates were incubated for 43 hours in a 5% CO 2 environment at
0
37 C. At the end of this period tritiated thymidine was added to each
well at a concentration of 1 pCi/0.05 mk. The plates were then incubated
for an additional 5 hours. The cells were harvested using a Mash II
harvester on glass fiber filters (Whatman, Inc., Clinton, New Jersey).
The fiber filters were then placed into counting vials containing 2 mk
counting fluid, Cytoscint (Westchem Enterprises, Inc., San Diego,
California). An LS - 250 liquid scintillation counter (Beckman
Instruments, Los Angeles, California) was used to count the 3H - thymidine incorporated into the DNA of the spleen cells. The results
obtained from the six - wells (three test wells and three control wells)
set up for every test and control animal wereaveraged.
Stimulation Index - S.I.
The stimulation index indicates the ability of PHA to stimulate
incorporation of

3
H - thymidine by test and negative control spleen

cells. Results were calculated as follows:
S.I. =

mean cpm test wells - mean cpm control wells
with PHA
without PHA
mean cpm control wells
without PHA

Relative Spleen Weight - R.S.W.
All test and control animals wereweighed prior to sacrifice.
The spleens were •removed immediately and weighed. The R.S.W. for
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each mouse was calculated as follows�
R.S.W.

spleen weight in mg
mouse weight in gm/10

=

Tumor Volume
Vernier calipers were used to make weekly measurements of
progressive H238 tumors.

The results were calculated as follows:

H1 =·height of leg at time-of H238 cell injection

H2 = height of leg with tumor at time of measurement

W = width of tumor
L

=

length of tumor

Tumor Volume

=

(H2 - H )
1
2

x

W

x

L

Statistical Analysis

The mean and standard error were calculated for all measurements

taken. These were used to cafrulate the probability of significance

using the 2-tail ed Student s t test.
I

11

II

Results
Cytotoxicity Assay Re�ults
1.

Anti body-Dependent Cell-Mediated Cytotoxicity
Results obtained for the antibody-dependent cell-mediated

cytotoxicity (ADCC) assay are summarized in Table II and Figure 2. In
all treatment groups except group 4 the progressive tumor mice had
lower levels .of ADCC activity than the no visible tumor (NVT) and re
gressor mice of that same group.

Group 6 animals showed the highest

level, or the least depression from the Oline, of ADCC activity for
progressor mice.
vi ty.

Groups 4 and.5 showed sliahtly lower levels of act�

Interestingly, group 2 mice receiving no . tumor ·therapy had ;a

sliahtly higher level of ADCC activity than did group 3 progressor mice
receiving a weekly treatment of levamisole. Note, however, that the

pertent ADCC was much higher for group 3 NVT and regressor mice. A sig
nificant difference in response was found between group 3 and group 6

progressor mice (See Table III for p values).
2.

Blocking Factor
Table II and Figure 3 summarize the cytotoxicity results obtained

in the blockina factor (BF) assays.

Untreated progressive tumor mice

(qroup 2) showed hiaher levels of BF than did any other group of
treated progressive tumor mice.

Group 4 animals possessed the lowest

or most deoressed levels of percent BF values found in progressors.
Group 3 progressor mice showed a somewhat higher BF level; however,
the NVT and rearessor mice in this group possessed the lowest percent
25

TABLE II, CYTOTOX I C I TY RESULTS
%ADCC a
Progress ors

d

Regressorse
& NVTf

%BF

b

%CTLc

Progressors d Regressors e Progressord
& NVT f

Regre5sorse
& NVIT

GROUP 2

-120.0±15.8

-87.4±22.8

10.3±30.6

10.4±37.5

-3.4±1.9

0.1±2.5

GROUP 3

-125.9±5.3

-56.5±31.8

7.5±12.3

-41.6±10.7

-1.3±1.8

-0.5±1.5

GROUP 4

-102.9±13.4

-14.2±15.4

25.7±29.4

-2.2±1.1

-3.9±1.2

GROUP 5

-100.6±15.0

-59.0±19.0

-11.2±12.9

10.5±23.6

-1.0±1.7

-0.5±2.7

GROUP 6

-87.7±15.8

-47.5±15.0

-2.8±9.6

3.0±3.6

-0.2±1.6

-104.9±4.6

-21.3±9.6

aPercent Antibody Dependent Cell Mediated Cytotoxicity
bPercent Blocking Factor
cPercent Cytolytic T Lymphocytes
dProgressors - mice with progressive tumors at the time of sacrifice
e
Regressors - mice with tumors that completely regressed before sacrifice
fNo Visible Tumors - mice with no visible tumors any time during the experiment
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TABLE III.

P values obtained for Tumor Volume, Relative Spleen Weight, Stimulation Index,
Blocking Factor, Cytolytic 1-Lymphocytes and Antibody-Dependent Cell-Mediated
Cytotoxicity Results (using the 2-tailed Student's "t" test)

Comparsion
Treatment Groups

Tumor
Mass

a
R.S.W,

b
S.I.

1 vs. 2

--

0.001

0.05

1 v... 3

--

0.001

0.1

1 vs. 4

--

0.001

0.05

1 vs. 5

--

0.001

0.01

1 vs. 6

--

0.001

0.05

2 vs. 3

--

0.1

2 vs. 4

--

2 vs. 5

---

2 vs. 6
3 vs. 4

'

0.1

0.05

0.1

0.1
,

3 vs. 5

-__

0.05r

3 vs. 6

--

0.1r

4 vs. 5

0.1

0.05

4 vs. 6
5 vs. 6

Spleen
c
ADCC

0.1

Cell
d
B.F.

' 0.05r
0.05r
0.05
0.1r

0.1

a Relative Spleen Weight at Sacrifice
Stimulation Index of Spleen Cells
Percent Antibody Dependent Cell Mediated Cytotoxicity
Percent Blocking Factor
Percent Cytolytic T Lymphocyte - Direct cytolysis
r Regressors - mice with tumors that completely regressed before sacrifice

0.1T
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e
•
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BF level of any group tested. As indicated in Figure 3, NVT and
regre�sor mice in groups 2, 4 and 5 were found to have higher levels
of blocking factor than did the progressive tumor mice in those same
groups. Significant p values for this assay are listed in Table III.
3.

Direct Cytolysis - (Cytolytic T-Lymphocytes)
Results obtained for the cytolytic T-lymphocyte (CTL) assays_are

summat'12ed in Table II and Figure 4. All NVT and regressor mice
other··than those found in group 4, which showed the greatest suppres
sion of'_CTL activity, showed hiqher direct cytolysis results than did.

the progressive tumor mice of the same group.· In comparing the pro

gressor mice, those in untreated group 2 showed the most suppression
of target cell lysis due to cytolytic T-lymphocytes. Results for
combination therapy group 6 progressor mice showed the most elevated,
or least depressed CTL results. Groups 3 and 5 progressor mice had
somewhat lower CTL activities.

Group 4 progressors showed an even

lower-�TL response to target tumor cells than groups 3 and 5. No
significant p values were obtained for this particular assay.
Lymphocyte Transformation Test Results
1.

Stimulation Index (S.I.) - Spleen Cells
Mean stimulation index results obtained from the lymphocyte

transformation test are summarized in Table IV and Figure 5. In all
groups the NVT and regressor mice had obviously higher.mean S.I.
values than did progressive tumor mice within the same group.
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TABLE IV.

STIMULATION INDEX RESULTS

GROUP 1

aPROGRESSORS

REGRESSORS &

d

GROUP 4

GROUP 5

GROUP 6

4.2±0,9

3,0±0.6

410±0.7

2,2±0.4

2.1.-±0.4

---

7,1±1.2

10.3±1.6

14.1±6.4

4.2±1.4

6.8±1.0

13,8±3.8

___

___

___

NVT MICE

NEGATIVE
CONTROLS

GROUP 3

___

b
c

GROUP 2

,

___

,
a

Progressors - mice with progressive tumors at the time of sacrifice

b Regressors - mice with tumors that completely regressed before sacrifice

cNo Visible Tumors - mice with no visible tumors any time during experiment
d

Negative Controls - non-injected mice injected only with saline)

15
14
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±3.8

EJ
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PROGRESSORS
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& REGRESSORS
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11

NEGATIVE CONTROLS
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Phytohemagglutinin (PHA) stimulated the spleen cells of the non
injected negative control mice in group 1 to a greater extent than
any other group of mice eicept for the NVT and regressor mice in
group 4. A significant difference was found between the group 1
mean S.I. value and those found for all other test groups.

Group

2 progressors al though not treated with any anti-tumor therapy had
a slightly higher mean S.I. than did any other group of progressive
tumor mice.

The mean S.I. found for group 2 progressors was sig

nificantly higher than those found for group 5 and 6 progressors.
.However, group 2 NVT and regressor mice did not show a significantly
higher S.I. than any other group of NVT and regressor mice._ Group
4 progressors treated only with�. patvum had a significantly higher
mean S.I. than did group 5 or 6 progressive tumor mice. The NVT and
regressor mice in this group showed a significantly higher S.I. value
than did group 5 and 6 NVT and regressors. Group 3 NVT and regressors
also had significantly highe�mean S.I. values than did groups 5 and
6 NVT and regressors. However, group 3 progressors were found to have
a lower S.I. value than progressors in groups 2 and 4, �nd only a
slightly higher NVT and regressor S.l. than found for groups 5 and 6.
Combination treatment group 6 progressors had the lowest mean S.I.
for any group tested. Table III gives the significant p values for
S.I. results.
Relative Spleen Weights (R�S.W.)
Table V and Figure 6 summarize the mean relative spleen weights
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and standard error calculated for each test group of mice at the time
of sacrifice. Mice with progressive tumors at the time of sacrifice
were found to have greatly enlarged spleens which is indicated by
high R.S.W. values. Negative control mice in group 1 had the lowest
R.S.W. 's for any experimental group.

Progressors within group 2 had

a lower mean R.S.W. than any other progressive tumor group. Progressors
in groups 3 and

6

showed the highest R.S.W.'s. Group 4 and 5 progressors

did not show significantly lower R.S.W.'s. All NVT and regressor mice
within any given treatment group had much lower R.S.W.'s than did- the
progressors within that same group. Table III gives the significant
p values for R.S�W. results.
Progressive Tumor Measurements
1.

Tumor Volume
Weekly calculations of tumor volume were made for each progressor

animal included in the experiment. Vernier calipers were used to take
the necessary measurements. The results. obtafned are depicted in
Figure 7.

No visible tumors were found in any of the negative control

group 1 mice throughout the study. Tumors appeared in groups 2, 3, 4
and 5 one week after the inejction of l x 10 6 H238 tu�or cells per

mouse. Group

6

had the slowest onset of tumor development. In this

group tumors did not appear until the second· week of therapy.
4 and

6

Group

mice showed the lowest mean tumor volume values at the end of

a seven w�ek treatment period. Group 5 mice treated with unblocked
lymphocytes and group 3 mice treated with levamisole showed even

TABLE V.

RELATIVE SPLEEN WEIGHTS

GROUP 1

GROUP

2

GROUP

3

GROUP

4

GROUP

5

GROUP

aPROGRESSORS

---

126.3±13.0

165.9±16.0

145.3±14.4

154.3±9.9

161.2±12.9

b
REGRESSORS &

---

44.0±1.6

41.9±1.8

61.6±12.0

46.0±2.4

59.8±5.4

c NVT

d
NEGATIVE CONTROLS

40.2±1.0

___

___

___

___

aProgressors - mice with progressive tumors at the time of sacrifice
bRegressors - mice with tumors that completely regressed before sacrifice
c

6

No Visible Tumors - mice with no visible tumors any time during the experiment
Negative Controls - non-injected mice (injected with saline only)
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greater mean tumor volumes at the end of the seven week period than
did the group 2 mice receiving no tumor therapy. Without exception,
once tumors began to develop, all groups. showed a weekly increase in
mean tumor volume.
2.

Tumor Incidence
Table VI and Figure 8 summarize the tumor incidence results

calculated for all six experimental groups of mice. Progressive
tumors were found within each group of mice except the non-injected
control group 1 mice. Groups 4 and 5 showed the highest progressive
tumor incidence, each at 83.3 percent. Group 2 mice receiving no tumor
therapy had a 66.7 percent progressor incidence. Mice in treatment groups
3 and 6 shared the lowest progressor incidence at 61.9 percent. Complete regression of observable tumors occured in only two mice during
the study. One mouse was in group 4, the other in group 5. One hundred
percent of the group 1 negative control mice failed to develop
observable tumors. These were classified as NUT mice. Groups 3 and 6
each showed 38.1 percent of their population to be NVT mice. Within
group 2, 33.3 percent were NUT mice. Groups 4 and 5 had a lower NVT
incidence at only 12.5 percent.
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TABLE VI.

INCIDENCE OF PROGRESSOR J REGRESSOR AND NO
VISIBLE TUMOR MICE
PROGRESSORS a

GROUP

1

GROUP

2

GROUP

3

GROUP

4

GROUP

5

GROUP

6

REGRESSORS b

NVT

C

100%

· (24/24)
33.3%

66.7%

(16/24)

(8/24)

61.9%

38.1%

(13/21)

(3/21)

83.3%

4.2%

12.5%

(20/24)

(1/24)

(3/24)

83.3%

4.2%

12.5%

(20/24)
61.9%

(13/21)

(1/24)

(3/24)

38.1%

(8/24)

aProgressors - mice with progressive tumors at the time of sacrifice
bRegressors - mice with tumors that complet�ly regressed before sacrifice
cNo Visible Tumors - mice with no visible tumors any time during the experiment
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DISCUSSION

The dependence of anti-tumor cell cytotoxicity upon antibody
Production was measured in the ADCC assay. Those mice bearing
progressive tumors at the time of sacrifice had more suppression
of ADCC against target cells than did NVT and regressor mice. Group
6, treated with a combination therapy of levamisole, C. parvum and unblocked lymphocytes over a seven week period had the highest, or
least depressed, level of ADCC activity for any group of progressor
mice. Group 3 progressors treated weekly only with 200 pqm of levamisole showed the lowest percent target cell lysis due to ADCC. NVT
and regressor mice in this same group, however, had one of the
highest ADCC activity levels (Figure 2).
It has been-suggested that the effectiveness of levamisole as
an anti-tumor chemotherapeutic agent is directly dependent upon the
initial immune status of the tumor host (Brulet-Rosset, et al.,
1978; Goldstein, 1978; Ameny, 1976) and the dose of levamisole administered (Focan, 1979). Therefore, the results obtained may indicate
that the immune status of the group 3 progressor mice was not initially
depressed to such an extent that would actually be enhanced by
levamisole administration. Just as plausible may be a lowered ADCC
activity due to too high a weekly dosage of levamisole. The 200 pgm
per mouse dosage was based on Bansal's (1978) work where an i.v. dose
of 1 mg per rat (equivalent of 5 gm/Kg rat weight) was used. Because
we were unable to successfully administer the treatments i.v., we

42

43

compensated by doubling the dosage and administering it i.p.
Those animals in our study with more active immune systems may
have been able to compensate for the immunosuppressive effects of
excessive amounts of levamisole. Group 4 progressor mice treated with
C. parvum, which non-specifically stimulates macrophanges, and group
5 progressors treated with unblocked lymphocytes showed higher ADCC
activity than did the group 3 progressors. C. parvum and unblocked
lymphocytes may then be the actual therapy combination that caused the
higher percent ADCC seen in group 6 progressor animals. However, an
enhanced synergistic effect may have been due •to the combination of
levamisole, C. parvum and unblocked lymphocytes.
Serum blocking factors may actually aid tumor cells in escaping
the host's immune surveillance system. Progressor mice would presumably possess higher levels of such blocking factors than would
NUT and regressor mice. In the results for the blocking factor (BF)
assay (Figure 3), group 2 progressors had a higher level of BF than
any other group of progressive\- tumor mice. This suggests that
individual tumor treatments or a combination of treatments may play
a role in lowering BF levels in a tumor host, thereby possibly
increasing direct or indirect tumor cell cytolysis by the immune
system of the host. Progressor mice in group 3 showed a level of
BF almost as high as the progressors in group 2. NUT and regressor
mice in group 3 possessed the lowest level of BE for any group of
mice charted. Results of the 200 ligm of levamisole administered
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alone again indicate an immunosuppressive role possibly related to
dosage (Sampson, 1977; ·sampson·, et �-, 1977).

Group 4 and 5 pro

gressors showed a -lower BF le�el than did the NVT and regressor
animals in these same groups.

NVT and regressors in group 4 had the

highest percent BF and the least Percent CTL.

Therefore, progres-

stve tumors in these animals may not be due to the anticytolytic

effect of BF in regard to tumor cells. Group 6 progressor animals
treated with a combi'natfon therapy of levamisole, f_. parvum and
unblocked lymphocytes were found to have higher levels of BF in
their serum than did either group 4 or 5 progressors. Levamisole
administered at too high a dosage may have acted as an antagonist and
minimized the beneficial effects of�- parvum and unblocked lymphocytes

together.

The direct cytolytic capabilities of T-lymphocytes is well

documented (Plata, et _tl., 1976; Hellstrom and Hellstrom, 1969).
The ability of T-cells to directly lyse H238 target tumor cells is
recorded in Figure 4. Progressive tumor mice in group 2 had the
least cytolytic T-lymphocyte (CTL) activity of progressors found in
any group. The NVT and reqressors found in group 2 however, had a
higher level of CTL activity than did any of the NVT and regressor

mice in treatment groups 3, 4, or 5. While the progressors in these

groups showed less inhibition of direct tumor cell cytolysis � vitro
than did group 2 progressors, the NVT and regressor mice abilities
to directly lyse target tumor cells was depressed even with therapy.
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Surprisingly, the combination of levamisole, C. parvum and unblocked
lymphocytes stimulated direct cytolysis by T-cells collected from
the group 6 NUT and regressor animals. The three treatments administered together appeared to have a synergistic effect on these mice.
Group 6 progressors also showed less suppression of CTL activity than
did any other group of progressive tumor mice.
The lymphocyte transformation test is used as a general indicator
of host immune cell responsiveness. The results found in Figure 5
indicate that spleen cells collected from non-injected mice in negative control group 1 showed comparatively high stimulation index
(S.I.) values. Lymphocytes collected from tumor-bearing hosts usually
are less stimulated by PHA than are cells collected from NUT and regressor mice and from normal, non-injected mice (Gillette and Boone,
1975; Sample, et al., 1971). Results from group 1 non-injected mice
followed such a pattern. In group 3, 4, 5 and 6 progressors the S.I.
was lower than for the group 2 progressors, indicating that all of
the anti-tumor treatments alone and in combination may have somehow
affected the responsiveness of the T-cells to PHA. Levamisole administered at too high a dosage is immunosuppressive (Sampson, et al.,
1977); while C. parvum is known to non-specifically stimulate macrophages, not necessarily T-cells (Ghaffar, et al., 1975; Ghaffar, et
al., 1974; Wolmack, 1974). Unblocking T-lymphocytes, however, would
be expected to increase the metabolic activity of the group 5 mice
(Doyle, 1974). This did not occur in our study.
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In each of these groups the NVT and regr�ssor mice had slightly
higher S.I. values than did the progressive tumor mice of that same
group. These results would be expected. Group 4 NVT and regressors
had a low S.I. value. Combined therapy group

6

progressors had the

lowest S.I. value for any group tested. This indicated that treat

ment with the combination of levamisole, �- parvum and unblocked

lymnhocytes associated with progressive tumor growth depressed the
T�cell activity level more than when each treatment was used individ

ually. However, the combination treatment did not significantly
depress the S.I. level.
Splenomegaly is often observed in �ice- bearing progressive
tumors (Nutter,.§!�., 1980; Rowland, et �.,1973). This pre
sumably occurs because of increases in blood cell formation and

cell sub-populations of the immune system migrating into the spleen
of tumor bearing animals. As would be expected, those mice in
negative control group 1, had the lowest R.S.W.s. Group 2, 3, 4,
5 and

6

progressive tumor mice all showed mean R.S.W.s much higher

than for the NVT and reqressor mice found within those same treatment
groups.

Tumors did not develop in any of the negative control group 1

mice. Tumors were found in group 2, 3, 4 and 5 mice one week after
injection of 1

x

106 H238 tumor cells into the right hind leg of each

animal. Steady increases in mean tumor volume proceeded for each of

these test groups until sacrifice. Group

6

progressors did riot show
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signs of tumor development until two weeks after H238 cell injection.
The combination of levamisole, C. parvum and unblocked lymphocytes
would appear to have delayed the development of tumors. In 1966,
Woodruff reported that C. parvum was able to delay tumor development.
He also noted that once the tumors were initiated, they progressed just
as quickly as those in hosts receiving no C. parvum treatment. Two
of the twenty progressors treated only with C. parvum (group 4)
developed tumors one week after initial tumor cell injection. It
appears that the C. parvum may have the ability to delay tumor
development.
Only one of the twenty progressors in group 5 treated only
with unblocked lymphocytes developed a tumor after the first week
of therapy. After the initial delay in appearance, tumors progressively enlarged on a weekly basis for group 4 and 5 mice just as
they did for the group 6 progressors. It was expected that group 2
progressors receiving no anti-tumor therapy would develop the
largest tumor volumes at the end of the seven week treatment period.
However, group 5 progressors treated with unblocked lymphocytes had
the largest mean tumor volume at the time of sacrifice, followed
closely by group 3 progressors. The results in group 5 may be
due to the administration of the unblocked lymphocytes i.p. rather
than i.v. as Bansal's (1978) group did.
The reason the administration route was changed was because of
the very small diameter of the mouse tail veins. Attempts to inject
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the unblocked lymphocytes into these veins were made but much of the
treatment sample was lost during injection. Standardization of cell
numbers would be very imprecise. It was decided, therefore, to use
an i.p. administration route.
·Throughout the seven week therapy period the mean tumor volumes

of these three groups did not differ significantly.· Progressor mice
treated with£. parvum alone (grouo 4) and in combination with
levamisole and unblocked lymphocytes (group 6) had the lowest
mean tumor volume at the end of the study. These tumor volumes did
differ significantly from those of group 5 (Table II). These results
indicate that£: parvum played a role in retarding tumor appearance
and reducing tumor volume.

These results coincide with results

.tl.· , 1978; Fisher, et .tl_. ,
1975; Currie and Bagshawe, 1970; Fisher, et .tl.-, 1970; Halpren,

obtained by other investigators (Bansa 1 , et
et �l . , 1966).

It was also found that the ADCC and BF test results positively
correlate with the tumor volume results found for group 4 and 6 mice.
This again indicates a role for£. parvum in enhancing the overall
immune status of progressor mice. Although the CTL results for
progressor mice were the least suppressed in the combination therapy

group 6 mice, the group 4 mice treated only with£. parvum showed a

much more depressed level of percent direct cytolysis. This might be
expected since£. parvum non-specifically stimulates macrophages, and

this particular test involves the ability of T-lymphocytes to directly
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lyse target tumor cells. While unblocked lymphocytes may have the
ability to delay tumor appearance, they seem to have no affect on
reducing tumor volume. Levamisole showed no apparent affect upon
tumor appearance or progression.
As would be expected, no visible tumors were found in any of
the negative control group 1 mice. Progressive tumors developed in
83.3 percent of the mice in groups 4 and 5. These were the only
two groups however, where complete regressors were found (one in
each group, but 33.3 percent of the mice never developed tumors.
6
Injections of 1 x 10 H238 cells per mouse were expected to cause
tumors in essentially 100 percent of the positive control mice
(Boyd and Orme, 1975).
Another TD
50 study would have to be performed before using
H238 cells again to determine at what cell concentration 100 percent
of the mice used would develop progressive tumors. With respect to the
results of the immune status testing, it was surprising that group 3
animals treated only with levamisole shared the lowest incidence of
tumor progression with those mice in group 6 (62.0 percent). In
Bansal's (1978) study of a rat tumor model, 1, 2-dimethylhydrazine
was used to initiate colon tumors. Treatment with a combination of
levamisole, C. parvum and unblocked lymphocytes resulted in 60.0
percent progressor mice, 20.0 percent regressor mice and 20.0
percent NVT mice. Our study employed the use of Balb/c H238,
HSV-2 transformed cells and we measured only the effects upon tumor
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promotion. Therefore, our slightly higher progressor tumor incidence
for combination therapy group 6 mice should not be surprising as
initiation of the tumor cells had already taken place before injection
into the test animals. Our NVT incidence was actually higher than that
recorded for Bansal's combination therapy group. However, we recorded
no regressors in comparison with his 20.0 percent figure. The group 6
animals developed tumors at the slowest rate and showed a lower mean
tumor volume than the group 3 animals.
Interestingly, our results correlate favorably with the ADCC and
CTL cytotoxicity results found for the group 6 progressors. This tends
to indicate that the combination of C. parvum with levamisole and unblocked lymphocytes does have an enhancing effect upon the immune
status of tumor, hosts, which may aid in lowering tumor incidence and
reducing tumor volume.

Conclusions
Some types of chemotherapeutic immunostimulation appear to be
able to increase specific activitie�_of a tumor host 1 s .immune�system�
However, because in vitro testing indicates that a particular anti
tumor therapy partially restores the normal immune response of a
host animal, this does not mean that all or any foreign tumor cells
will acutally be destroyed.
This particular study indicated tha levamisole administered at
the dosage of 200 µgm per mouse had no stimulatory affect upon the
host's immune system.

It may have acted in some fashi.on to reduce

the overall tumor incidence of group 3 mice (although no significant
difference was found between group 3 and any other test group of mice
including group 2 untreated mice).

However, this study did not include

any inmunological measurements that would explain this lower tumor
incidence.

f. parvum used as an irrmunostimulator was somewhat effective in

decreasing the suppression of ADCC activity in comparison with group
2 mice.

The BF level appeared to be lower than that found for pro

gressors in the positive control group also.

Mean tumor volume was

significantly reduced in group 4 progressors and tumor appearance was
delayed in comparison with group 2 and 3 mice.

Therefo_re,

f. parvum

does have a potential role in tumor therapy.
Group 5 mice treated only with unblocked lymphocytes showed
51

52

slight increases in ADCC and CTL activity along with a lower level
of BE activity than those mice in group 2. However, the mean tumor
volume for this group was even higher than for the positive controls.
Also, tumor incidence was the highest in this group of mice. It does
not appear from this study that unblocked lymphocytes administered
alone have a significant role in tumor therapy.
Combining the three chemotherapeutic agents appeared to increase
the overall immune responsiveness of the test animals as indicated by
the ADCC and CTL results. Although this immune stimulation may well
be responsible for the lower tumor incidence and the lower mean tumor
volume found for this study group, the treatments used in combination
would have to be further divided and studied in order to definitely
determine which of the three therapeutic agents or combination of
agents were the most stimulatory. The combination administered to
group 6 animals did play.a role in delaying the appearance of progressive tumors and reducing tumor incidence.
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